Spyre Therapeutics, Inc. (SYRE)
107.40
+0.75
(+0.70%)
USD |
NASDAQ |
Aug 25, 12:19
Spyre Therapeutics Enterprise Value : 8.393B for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 8.393B |
| August 21, 2026 | 8.379B |
| August 20, 2026 | 8.494B |
| August 19, 2026 | 8.593B |
| August 18, 2026 | 8.496B |
| August 17, 2026 | 8.213B |
| August 14, 2026 | 8.127B |
| August 13, 2026 | 7.970B |
| August 12, 2026 | 8.168B |
| August 11, 2026 | 8.049B |
| August 10, 2026 | 8.277B |
| August 07, 2026 | 8.240B |
| August 06, 2026 | 8.109B |
| August 05, 2026 | 8.191B |
| August 04, 2026 | 8.243B |
| August 03, 2026 | 7.361B |
| July 31, 2026 | 7.660B |
| July 30, 2026 | 7.940B |
| July 29, 2026 | 7.620B |
| July 28, 2026 | 7.804B |
| July 27, 2026 | 7.811B |
| July 24, 2026 | 7.995B |
| July 23, 2026 | 7.807B |
| July 22, 2026 | 7.734B |
| July 21, 2026 | 8.045B |
| Date | Value |
|---|---|
| July 20, 2026 | 7.572B |
| July 17, 2026 | 7.828B |
| July 16, 2026 | 7.290B |
| July 15, 2026 | 7.990B |
| July 14, 2026 | 7.715B |
| July 13, 2026 | 7.255B |
| July 10, 2026 | 7.608B |
| July 09, 2026 | 7.697B |
| July 08, 2026 | 7.402B |
| July 07, 2026 | 7.299B |
| July 06, 2026 | 6.816B |
| July 02, 2026 | 6.630B |
| July 01, 2026 | 6.829B |
| June 30, 2026 | 6.819B |
| June 29, 2026 | 6.523B |
| June 26, 2026 | 6.344B |
| June 25, 2026 | 6.405B |
| June 24, 2026 | 6.214B |
| June 23, 2026 | 7.066B |
| June 22, 2026 | 7.324B |
| June 18, 2026 | 6.379B |
| June 17, 2026 | 6.312B |
| June 16, 2026 | 5.990B |
| June 15, 2026 | 6.004B |
| June 12, 2026 | 5.784B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AbbVie, Inc. | 531.73B |
| vTv Therapeutics, Inc. | 46.84M |
| BridgeBio Pharma, Inc. | 18.52B |
| Praxis Precision Medicines, Inc. | 9.517B |
| ACADIA Pharmaceuticals, Inc. | 4.221B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -36.20M |
| Total Expenses (Quarterly) | 36.20M |
| EPS Diluted (Quarterly) | -0.4272 |
| Earnings Yield | -2.03% |
| Normalized Earnings Yield | -2.097 |